| Reference | Drug regimen | Result | Number patients | Age | Location | Year |
| Ngasala BE et al[1] | Artemether-lumefantrine | High efficacy | 359 | Children | Tanzania | 2011 |
| Achan J et al[2] | Artemether-lumefantrine versus quinine | Artemether-lumefantrine superior | 175 | Children | Uganda | 2009 |
| Dorsey G et al[3] | Artemether-lumefantrine verus artesunate-amodiaquine versus amodiaquine-sulfadoxine-pyrimethamine | Artemether-lumefantrine superior | 601 | Children | Uganda | 2007 |
| Zwang J et al[4] | Artemether-lumefantrine versus artesunate-amodiaquine | Artesunate-amodiaquine was followed by fewer recurrences | 602 | Children | Uganda | 2016 |
| Toure O et al[5] | Artemether-lumefantrine versus arterolane maleate-piperaquine phosphate | Comparable efficacy and safety | 859 | Children | Africa and India | 2017 |
| Thriemer K et al[6] | Artemether-lumefantrine versus artesunate-azithromycin | Equivalent cure rates | 228 | Adults and children | Bangladesh | 2010 |
| Zwang J et al[7] | Artesunate-amodiaquine versus non-ACT therapy | Artesunate-amodiaquine superior to non-ACT therapy | 11,700 | Adults and children | Multi-country | 2009 |
| Tahar R et al[8] | Artesunate-amodiaquine versus atovaquone-proguanil versus artesunate-atovaquone-proguanil | Equivalent efficacies by PCR; slower clearance with atovaquone-proguanil arm versus artesunate-atovaquone-proguanil | 338 | Children | Cameroon | 2014 |
| Sirima S et al[9] | Artesunate-mefloquine versus artemether-lumefantrine | Comparable efficacy with similar rates of adverse events | 945 | Children | Burkina Faso, Kenya, and Tanzania | 2016 |
| Smithuis F et al[10] | Artesunate-mefloquine versus artesunate-amodiaquine versus dihydroartemisinin-piperaquine versus artemether-lumefantrine | Artesunate-mefloquine greatest posttreatment suppression | 808 | Adults and children | Myanmar | 2010 |
| Rueangweerayut R et al[11] | Artesunate-mefloquine versus pyronaridine-artesunate | Similar efficacies; longer parasite clearance times with pyronaridine-artesunate | 1271 | Adults and children | Multi-country | 2012 |
| Sagara I et al[12] | Either pyronaridine-artesunate or dihydroartemisinin-piperaquine versus either artesunate-amodiaquine or artemether-lumefantrine | Pyronaridine-artesunate and dihydroartemisinin-piperaquine noninferior to artesunate-amodiaquine and artemether-lumefantrine | 4710 | Adults and children | Burkina Faso, Guinea, and Mali | 2018 |
| Zani B et al[13] | Dihydroartemisinin-piperaquine versus other ACTs | In Africa: Dihydroartemisinin-piperaquine reduces treatment failure compared with artemether-lumefantrine, (though both with PCR-adjusted failure rates <5%) In Asia: Dihydroartemisinin-piperaquine as effective as artesunate-mefloquine | 16,382 | Adults and children | Multi-country | 2014 |
| Wanzira H et al[14] | Dihydroartemisinin-piperaquine versus artemether-lumefantrine | Dihydroartemisinin-piperaquine superior | 312 | Children | Uganda | 2014 |
| Yeka et al[15] | Dihydroartemisinin-piperaquine artemether-lumefantrine | Regimens equivalent for treatment of uncomplicated Plasmodium falciparum malaria | 599 | Children | Uganda | 2019 |
| Pryce et al[16] | Pyronaridine-artesunate compared with alternative ACTs | Pyronaridine-artesunate efficacious against uncomplicated P. falciparum malaria; treatment failure rate of <5% at days 28 and 42; may be at least as good as or better than other ACTs | 5711 | Adults and children | Multicountry, Africa, and Asia | 5 studies published up until October 2021 |
